Press Release

Sameer Joshi                                
Call: +912067274191
Email: [email protected]

Pune, January 30,2020 – Diabetic retinopathy (DR) is a medical condition of the eye, which is prevalent in a diabetic individual. It is mainly caused due to damage of the blood vessels of the light-sensitive tissue present at the back of the eye. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the forecast period due to increase in prevalence of diabetes worldwide, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment in focus on awareness which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs limit it. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are projected to provide several opportunities for the market growth.

Get Sample PDF For More Professional And Technical Insights at: https://www.premiummarketinsights.com/sample/AMR00013203

The diabetic retinopathy market is segmented on the basis of type, treatment type, and region. Based on type, the market is bifurcated into proliferative DR and diabetic macular edema (DME). On the basis of treatment type, diabetic retinopathy market is segmented into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. The market is analyzed based on four geographical regions, which include North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.
Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.
This study provides the competitive landscape of the market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise diabetic retinopathy market conditions are comprehensively analyzed in the report to understand the regional trends and dynamics.

Diabetic Retinopathy Market Key Segments:

By Type

Proliferative Diabetic Retinopathy
Diabetic Macular Edema (DME)

By Treatment Type

Anti VEGF Drug
Steroid Implants
Laser Surgeries
Vitrectomy

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Purchase Complete Report at: https://www.premiummarketinsights.com/buy/AMR00013203

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

This post was originally published on The Picayune Current